PO.ET02.07 · 实验与分子治疗
Innovative Therapeutic Modalities and Translational Platforms
-
283 · PDF 人类肿瘤中的严重酸性用于pH可激活的细胞因子疗法 Severe acidity in human tumors for pH-activatable cytokine therapy Qiang Feng, Jun Chen, William Hartnett, Raymundo Pantoja, Gang Huang, Isaac Chan, Baran Sumer, Jinming Gao
-
284 · PDF 从不可成药到可干预:致癌转录因子小分子调节剂的转录组学发现 From undruggable to actionable: Transcriptomic discovery of small-molecule modulators of oncogenic transcription factors Arianna Sabò, QUANTRO's Team
-
285 · PDF NEBNext UltraShear® Long Read:用于临床相关样本长读长测序的酶法DNA片段化 NEBNext UltraShear ® Long Read: Enzymatic DNA fragmentation for long read sequencing of clinically relevant samples Keerthana Krishnan, Brittany S. Sexton, Matt Angel, Karen McKay, Jonathan Sanford, Ruby Moulton, Louise Williams, Bradley W. Langhorst, Pingfang Liu, V.K. Chaithanya Ponnaluri
-
286 · PDF 用于免疫肿瘤学候选药物风险评估和功能评价的新方法学 New approach methodologies for risk assessment and functional evaluation of immuno-oncology drug candidates Christoph Schifflers, Martijn Vlaming, Sofie Pattyn
-
287 · PDF 化学连接蛋白实现p53翻译后修饰的定量ELISA Chemically ligated proteins enable quantitative ELISAs for p53 post-translational modifications Thomas Bailey
-
288 · PDF 配对 NanoLuc® 与红移 NanoPrism™ 荧光素酶的双色生物发光分析 Two-color bioluminescence analyses pairing NanoLuc® and red-shifted NanoPrism™ luciferases Juliano Alves, Karilyn Porter, Mike Killoran, Robin Hurst, Mark Klein, Debayan De Bakshi, Rahele Esmatpour, James J. Cali, Thomas Machleidt, Rachel F. Ohana, Hicham Zegzouti
-
289 · PDF 追踪 APOBEC3A 以克服肺癌耐药 Tracking APOBEC3A to overcome drug resistance in lung cancer Maria Vittoria Di Marco, Christopher Eggers, Aaron N. Hata
-
290 · PDF 基于 ICH 指南制定适当残留溶剂标准的科学依据 Scientific justification for setting up an appropriate specification of residual solvent based on ICH guideline Zhanxiang Sun, Jianqiang Li, Lynn Wang, Xudong Wei
-
291 · PDF PHD2-HDAC 双重抑制剂 31c 预防顺铂-贝伐珠单抗肾毒性并保持宫颈癌抗肿瘤疗效 Dual PHD2-HDAC inhibitor 31c prevents cisplatin-bevacizumab nephrotoxicity and preserves antitumor efficacy in cervical cancer Xi Chen, Dongyu Han, Xiaohua Kong, Wenfeng Gou, Yang Song, Huiqiang Wei, Yiliang Li, Yong Qin
- 292 292 AOH1996,一种癌症相关 PCNA 抑制剂,恢复尿路上皮癌的铂类敏感性:体外和体内研究 AOH1996, a cancer-associated PCNA inhibitor, restores platinum sensitivity in urothelial carcinoma: In vitro and in vivo study Kuan-Lin Kuo, Kuo-How Huang, Yi Ju (Ellen) Kao, Chen-Hsun Hsu
-
293 · PDF 韩国结直肠癌患者抗癌药物使用情况分析 Anti-cancer drug usage analysis among Korean patients with colorectal cancer Yu Jin Lim, Jeongseon Kim
-
294 · PDF 比较性生化激酶活性分析确定 lirafugratinib 为高选择性 FGFR2 抑制剂 Comparative biochemical kinase activity analysis identifies lirafugratinib as a highly selective FGFR2 inhibitor Alison M. Schram, Grace Lee, Tracey Wei, Seong Jang, Kristin Ryan
-
295 · PDF 新型丙酮酸激酶 M2(PKM2)抑制剂阿昔洛韦在实验性食管腺癌中的抗肿瘤作用 Antitumor effect of a new pyruvate kinase M2 (PKM2) inhibitor Acyclovir in experimental esophageal adenocarcinoma Md Sazzad Hassan, Mallory Turner, Elizabeth Heffernan, Katherine Millett, Oliver O’Reilly, Niranjan Awasthi, Usama Usama, Aktar Ali, Urs von Holzen
-
296 · PDF 巨大戟烷型二萜类化合物用于BL2型三阴性乳腺癌的评价 Evaluation of ingenane diterpenoids for BL2 triple-negative breast cancer Pamela R. Duarte, April L. Risinger
- 297 297 Cymirafen:一种按每周方案递送极高强度短脉冲MMAE的蛋白-药物偶联物 Cymirafen: A protein-drug conjugate that delivers very intense short pulses of MMAE on a weekly schedule Maria Carmen Mulero Roig, Sukshala A. Jadhav, Willie Pi, Stephen B. Howell
- 298 298 一种携带VEXAS综合征中常见UBA1突变的工程化人髓系细胞系对蛋白酶体抑制剂硼替佐米敏感 An engineered human myeloid cell line with a UBA1 mutation frequently detected in VEXAS syndrome is sensitive to the proteasome inhibitor bortezomib Hina Yazawa, Youhei Sasaki, Norihiko Kawamata
-
299 · PDF 从工厂到患者:体内表达生物制剂作为免疫治疗生产的新范式 From factory to patient: In vivo ‑expressed biologics as a new paradigm for immunotherapy manufacturing Henry Leonard, Dan Rocca, Philipp Meyer, Ina Rohleff, Eva Oswald, Sarah L. Martin, Matthew Benson, Namrata Jayanth, Christian Cobaugh, Michael Shaw, Julia Schueler, Gemma Moiset, Roxana Redis, Louise Brackenbury, Justin Bryans
-
300 · PDF 绘制细胞命运图谱:从代谢动态到DNA损伤反应 Mapping cellular fate: From metabolic dynamics to DNA damage responses Lorena Sueiro-Ballesteros, Henry Leonard, Dan Rocca, Lauren Schewitz-Bowers, Louise Brackenbury
-
301 · PDF 给予纳米免疫偶联物贝伐珠单抗后nab-紫杉醇的群体药代动力学 Population pharmacokinetics of nab-paclitaxel following administration of a nano-immunoconjugate with bevacizumab Mohd Beshr Chama, Matthew Stephen Block, Vera J. Suman, Joel M. Reid
- 302 302 评价胆固醇含量对纳米脂质体制剂抗葡萄膜黑色素瘤细胞摄取和制剂活性的影响 Evaluating the influence of cholesterol content on the cellular uptake and formulation activity of nanoliposomal formulations against uveal melanoma Shrey Mehulkumar Patel, Francielle Mourisso, Bilal Habibeh, Anna Kleckerova, Robert B. Campbell
-
303 · PDF 将肿瘤转变为治疗性药物工厂:跨肿瘤适应证的疗效 Turning tumors into therapeutic drug factories: Efficacy across oncology indications Moataz Reda, Blaine McCarthy, Sushil Lathwal, Evan Bishop, Priyanka Balasubrahmanyam, Robby Chandra, Nikki Kimura, Xiao Wu, Kim Tran, Jesse Simons, Ajda Rojc, Jayalakshmi Ramani, Dang Dang, David Rosen, Badri Ananthanarayanan, Nadege Morisot, David Suhy
- 304 304 一项瘤内注射超高浓度一氧化氮(UNO)气体治疗皮肤及皮下实体瘤转移灶的1期研究 A phase 1 study of intratumoral ultra-high concentration nitric oxide (UNO) gas injection in cutaneous and subcutaneous solid tumor metastases Amichay Meirovitz, Steve Lisi, Kim Sheva, David Greenberg, John Jett
- 305 305 电化学疗法治疗非黑色素瘤皮肤癌:临床结局与耐受性 Non-melanoma skin cancer treated with electrochemotherapy: Clinical outcomes and tolerability Felipe Horacio Maglietti, Raquel Lertora, Nazarena S. Martinez, Alexandre Da Rosa Silva, Marina Ribeiro Damasceno Silva, Sebastian D. Michinski
- 306 306 整合计算与功能基因组学方法揭示UBE2Z-UBR2-E-钙黏蛋白轴是结直肠癌中β-catenin特异性的脆弱靶点 Integrative computational and functional genomic approach reveals UBE2Z-UBR2-Ecadherinaxis as a beta-catenin-specific vulnerability in colorectal cancer Chunhua Wan, Hugh Gao, Claire Sun, Ron Firestein
- 307 307 CCN5通过Merlin/NF2和Orai-1分子特征介导三阴性乳腺癌生长和转移的抑制 Triple-negative breast cancer growth and metastasis suppression by CCN5 is mediated by Merlin/NF2 and Orai-1 molecular signatures Inamul Haque, Gargi Maity, Jamie L. Porter, Snigdha Banerjee, Sushanta K. Banerjee
- 308 308 褪黑素在子宫平滑肌瘤和平滑肌肉瘤细胞系中的活性:一项关于其对间叶源性肿瘤抑制潜力的初步研究 Melatonin activity in uterine leiomyoma and leiomyosarcoma cell lines: A preliminary study of its inhibitory potential in mesenchymal tumors Tatielly T. Miranda, Edmund C. Baracat, Roseli S. Soares, Katia C. Carvalho
-
309 · PDF MUC13与NDRG1信号传导在肝癌中的致癌协同作用 Oncogenic cooperation of MUC13 and NDRG1 signaling in liver cancer Shabnam Malik, Mohammed Sikander, Daniel Zubieta, Mirza Sarwar Baig, Iris Enriquez, Murali M. Yallapu, Subhash C. Chauhan
- 310 310 NEU-002的转化开发:工程化治疗性弹性蛋白酶通过腹腔内和静脉给药展现出全身性抗肿瘤活性 Translational development of NEU-002: Engineered therapeutic elastases demonstrate systemic anti-tumor activity via intraperitoneal and intravenous administration Maria Fumagalli, Chang Cui, Ravindra Gujar, Nicole Martinez, Peter Haberz, Court Turner, Lev Becker
- 311 311 生产功能性重组蛋白以推进自身免疫性疾病治疗的整合策略 Integrated strategies for producing functional recombinant proteins to advance autoimmune disease therapeutics Wenlin Ren, Siwen Wang, An Ouyang, Spencer Chiang, Yu Sun
- 312 312 基于L.paracasei NPB01与L.rhamnosus GG序贯发酵的后生元对乳腺癌发挥抗肿瘤活性 Postbiotic based on sequential fermentation of L.paracasei NPB01 and L.rhamnosus GG exerts antitumor activities against breast cancer Roberto Berni Canani, Chiara Luongo, Laura Pisapia, Franca Oglio, Roberta Di Santillo, Alessia Gaeta, Chiara Scocco, Marco Michelini, Vittoria Mauriello, Alessia Cadavere, Camilla Messuri, Saranya Chumsri, Dawn Mussallem